Effect of the Antidepressant Org 3770 on Human Sleep

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1990 Jan 1

PMID 2373128

Citations 19

Authors

G S Ruigt

B Kemp

C M Groenhout

H A Kamphuisen

Affiliations

Soon will be listed here.

Abstract

The effect of a single dose (30 mg) of Org 3770 (metirzapine) on human sleep was assessed in a double blind, placebo controlled, cross over study in 6 young, healthy male volunteers. The sleep stage classification was based on visual scoring of 24 h electroencephalographic recordings according to the criteria of Rechtschaffen and Kales. Org 3770 30 mg p.o. given 2 h before bedtime had a sleep promoting action in all subjects, resulting in a shortened time to the onset of sleep. Bedtime waking and dozing (Stage 1) were reduced in favour of deep, slow wave sleep (Stages 3 and 4). Org 3770 increased the latency of REM sleep with respect to Stage 2 sleep in all subjects. It also caused a minor reduction in waking periods during REM sleep and a lower frequency of awakenings after periods of movement. No effect of Org 3770 was observed in reaction and vigilance tests on the post treatment day. The observed effects of Org 3770 on normal human sleep suggest that it might ameliorate the sleep disturbances encountered in endogenous depression, which are characterized by a reduction in slow wave sleep, an increase in nighttime awakenings and shortening of REM sleep latency.

Citing Articles

Sleep Dysfunction in Huntington's Disease: Impacts of Current Medications and Prospects for Treatment.

Owen N, Barker R, Voysey Z J Huntingtons Dis. 2023; 12(2):149-161.

PMID: 37248911 PMC: 10473096. DOI: 10.3233/JHD-230567.

Managing Sleep in Adults with ADHD: From Science to Pragmatic Approaches.

Surman C, Walsh D Brain Sci. 2021; 11(10).

PMID: 34679425 PMC: 8534229. DOI: 10.3390/brainsci11101361.

Mirtazapine-associated movement disorders: A literature review.

Rissardo J, Caprara A Tzu Chi Med J. 2020; 32(4):318-330.

PMID: 33163376 PMC: 7605300. DOI: 10.4103/tcmj.tcmj_13_20.

Depression and Sleep.

Steiger A, Pawlowski M Int J Mol Sci. 2019; 20(3).

PMID: 30708948 PMC: 6386825. DOI: 10.3390/ijms20030607.

The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression.

Wang Y, Li R, Zhang M, Zhang Z, Qu W, Huang Z Curr Neuropharmacol. 2015; 13(4):543-53.

PMID: 26412074 PMC: 4790401. DOI: 10.2174/1570159x13666150310002540.

References

Kupfer D . REM latency: a psychobiologic marker for primary depressive disease. Biol Psychiatry. 1976; 11(2):159-74. View

KARCZMAR A, LONGO V, de Carolis A . A pharmacological model of paradoxical sleep: the role of cholinergic and monoamine systems. Physiol Behav. 1970; 5(2):175-82. DOI: 10.1016/0031-9384(70)90061-2. View

Claghorn J, JOHNSTONE E, Studebaker S, Ajeman S . The effectiveness of 6-azamianserin (Org 3770) in depressed outpatients. Psychopharmacol Bull. 1987; 23(1):160-1. View

McCarley R, Hobson J . Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science. 1975; 189(4196):58-60. DOI: 10.1126/science.1135627. View

Ruigt G, van Proosdij J, Van Wezenbeek L . A large scale, high resolution, automated system for rat sleep staging. II. Validation and application. Electroencephalogr Clin Neurophysiol. 1989; 73(1):64-71. DOI: 10.1016/0013-4694(89)90020-5. View

Vogel G . Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1983; 7(2-3):343-9. DOI: 10.1016/0278-5846(83)90122-7. View

Fink M, Irwin P . Pharmaco-EEG study of 6-azamianserin (ORG 3770): dissociation of EEG and pharmacologic predictors of antidepressant activity. Psychopharmacology (Berl). 1982; 78(1):44-8. DOI: 10.1007/BF00470586. View

Vogel G, Vogel F, McAbee R, Thurmond A . Improvement of depression by REM sleep deprivation. New findings and a theory. Arch Gen Psychiatry. 1980; 37(3):247-53. DOI: 10.1001/archpsyc.1980.01780160017001. View

Ruigt G, van Proosdij J, Van Delft A . A large scale, high resolution, automated system for rat sleep staging. I. Methodology and technical aspects. Electroencephalogr Clin Neurophysiol. 1989; 73(1):52-63. DOI: 10.1016/0013-4694(89)90019-9. View

10.

OConnor W, Leonard B . Effect of chronic administration of the 6-aza analogue of mianserin (Org. 3770) and its enantiomers on behaviour and changes in noradrenaline metabolism of olfactory-bulbectomized rats in the "open field" apparatus. Neuropharmacology. 1986; 25(3):267-70. DOI: 10.1016/0028-3908(86)90250-9. View

11.

van Sweden B, Kemp B, Kamphuisen H, van der Velde E . Alternative electrode placement in (automatic) sleep scoring (Fpz-Cz/Pz-Oz versus C4-A1). Sleep. 1990; 13(3):279-83. DOI: 10.1093/sleep/13.3.279. View

12.

de Boer T, Maura G, Raiteri M, de Vos C, Wieringa J, Pinder R . Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988; 27(4):399-408. DOI: 10.1016/0028-3908(88)90149-9. View

13.

Kemp B, Kamphuisen H . Simulation of human hypnograms using a Markov chain model. Sleep. 1986; 9(3):405-14. DOI: 10.1093/sleep/9.3.405. View

14.

Nickolson V, Wieringa J, Van Delft A . Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn Schmiedebergs Arch Pharmacol. 1982; 319(1):48-55. DOI: 10.1007/BF00491478. View